[go: up one dir, main page]

AR092475A1 - Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r - Google Patents

Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r

Info

Publication number
AR092475A1
AR092475A1 ARP130103184A ARP130103184A AR092475A1 AR 092475 A1 AR092475 A1 AR 092475A1 AR P130103184 A ARP130103184 A AR P130103184A AR P130103184 A ARP130103184 A AR P130103184A AR 092475 A1 AR092475 A1 AR 092475A1
Authority
AR
Argentina
Prior art keywords
methods
atopic dermatitis
antagonist
administration
treat atopic
Prior art date
Application number
ARP130103184A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092475(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma, Sanofi Sa filed Critical Regeneron Pharma
Publication of AR092475A1 publication Critical patent/AR092475A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente proporciona métodos para tratar la dermatitis atópica (DA). También se proporcionan métodos para mejorar uno o más parámetros asociados con la DA, y métodos para reducir el nivel de al menos un biomarcador asociado con la DA en un sujeto que lo necesita. Los métodos de la presente comprenden administrar a un sujeto que lo necesita una composición farmacéutica que comprende un antagonista del receptor de interleucina-4 (IL-4R) tal como un anticuerpo anti-IL-4R.
ARP130103184A 2012-09-07 2013-09-06 Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r AR092475A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261697972P 2012-09-07 2012-09-07
US201261738715P 2012-12-18 2012-12-18
US201361748588P 2013-01-03 2013-01-03
US201361764624P 2013-02-14 2013-02-14
US201361768229P 2013-02-22 2013-02-22
US201361770091P 2013-02-27 2013-02-27
US201361782420P 2013-03-14 2013-03-14
US201361816191P 2013-04-26 2013-04-26
FR1356759 2013-07-10

Publications (1)

Publication Number Publication Date
AR092475A1 true AR092475A1 (es) 2015-04-22

Family

ID=50233497

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103184A AR092475A1 (es) 2012-09-07 2013-09-06 Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r

Country Status (29)

Country Link
US (2) US20140072583A1 (es)
EP (5) EP4649999A2 (es)
JP (4) JP6353838B2 (es)
KR (3) KR102122708B1 (es)
CN (3) CN118286417A (es)
AR (1) AR092475A1 (es)
AU (4) AU2013312868B2 (es)
BR (1) BR112015005048A8 (es)
CA (1) CA2883936C (es)
CY (1) CY1121906T1 (es)
DK (1) DK2892927T3 (es)
ES (2) ES2981062T3 (es)
HR (1) HRP20181227T1 (es)
HU (2) HUE039387T2 (es)
IL (1) IL237328B (es)
LT (1) LT2892927T (es)
MX (1) MX363193B (es)
NZ (3) NZ748451A (es)
PL (1) PL2892927T3 (es)
PT (2) PT3889181T (es)
RS (1) RS57520B1 (es)
RU (2) RU2698907C2 (es)
SG (2) SG11201501011WA (es)
SI (1) SI2892927T1 (es)
SM (1) SMT201800396T1 (es)
TR (1) TR201808181T4 (es)
TW (4) TWI690328B (es)
UY (1) UY35013A (es)
WO (1) WO2014039461A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
ES2981062T3 (es) * 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
EP3613432B1 (en) 2013-06-21 2025-08-06 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
CA2950945A1 (en) * 2014-06-17 2015-12-23 Xycrobe Therapeutics, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
RU2736732C2 (ru) 2015-04-02 2020-11-19 Интервет Интернэшнл Б.В. Антитела к альфа-рецептору собачьего интерлейкина-4
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
ES2983475T3 (es) * 2016-02-19 2024-10-23 Regeneron Pharma Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R
SG11201807421TA (en) * 2016-03-01 2018-09-27 Corcept Therapeutics Inc The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP4442323A3 (en) * 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
EP4345110A3 (en) 2016-09-22 2024-06-12 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
RU2752785C2 (ru) 2016-09-23 2021-08-04 Дженентек, Инк. Применение антагонистов il-13 для лечения атопического дерматита
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
FI3658184T3 (fi) * 2017-07-27 2023-11-30 Alexion Pharma Inc Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
KR102859911B1 (ko) * 2017-10-31 2025-09-16 원니스 바이오테크 컴퍼니 리미티드 IgE-매개 알레르기성 질환들의 치료
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
CN111656382A (zh) * 2018-01-31 2020-09-11 美道寻济株式会社 广告提示方法及广告提示系统
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
EP3833350A4 (en) 2018-08-10 2022-05-18 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
WO2020092015A1 (en) * 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
CN111494626B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
TW202519263A (zh) * 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN111592597B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
US11748800B1 (en) * 2019-09-11 2023-09-05 Life Spectacular, Inc. Generating skin care recommendations for a user based on skin product attributes and user location and demographic data
US12277100B2 (en) 2019-09-12 2025-04-15 Life Spectacular, Inc. Maintaining user privacy of personal, medical, and health care related information in recommendation systems
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
BR112022011098A2 (pt) 2019-12-09 2022-09-20 Sanofi Biotechnology Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados
AU2021244266A1 (en) 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist
US12102710B2 (en) 2020-06-23 2024-10-01 Crown Laboratories, Inc. Probiotic skin formulations
JP2023548474A (ja) * 2020-11-09 2023-11-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を処置する方法
IL303135A (en) 2020-12-23 2023-07-01 Numab Therapeutics AG Antibody variable domains that bind IL-4R
EP4019090A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-4r
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
US11581084B2 (en) * 2020-12-29 2023-02-14 Kpn Innovations, Llc. Systems and methods for generating an alimentary plan for managing skin disorders
WO2022178540A1 (en) * 2021-02-18 2022-08-25 Aclaris Therapeutics, Inc. Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions
AU2022333073A1 (en) 2021-08-23 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2023130010A1 (en) * 2021-12-30 2023-07-06 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
CN120129522A (zh) * 2022-10-06 2025-06-10 瑞格拉尼昂有限责任公司 用于治疗化脓性汗腺炎的方法和组合物
WO2024097714A1 (en) 2022-11-01 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3315427B2 (ja) * 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
EP1304115B1 (en) * 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
RU2453303C1 (ru) * 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
ES2981062T3 (es) * 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
AU2021357078A1 (en) 2020-10-05 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating asthma in pediatric subjects by administering an il-4r antagonist

Also Published As

Publication number Publication date
AU2019279946B2 (en) 2021-07-01
TW202325341A (zh) 2023-07-01
AU2013312868B2 (en) 2018-03-22
NZ748451A (en) 2023-04-28
US20140072583A1 (en) 2014-03-13
KR102122708B1 (ko) 2020-06-17
JP6637113B2 (ja) 2020-01-29
PT3889181T (pt) 2024-05-29
PL2892927T3 (pl) 2018-11-30
AU2019279946A1 (en) 2020-01-16
SG10201701798TA (en) 2017-04-27
UY35013A (es) 2014-03-31
MX363193B (es) 2019-03-14
KR102576903B1 (ko) 2023-09-13
NZ630178A (en) 2017-06-30
CN118286417A (zh) 2024-07-05
TR201808181T4 (tr) 2018-07-23
LT2892927T (lt) 2018-09-10
EP3889181A1 (en) 2021-10-06
BR112015005048A8 (pt) 2018-01-30
SMT201800396T1 (it) 2018-09-13
CA2883936C (en) 2022-01-11
ES2675779T3 (es) 2018-07-12
RU2018131237A3 (es) 2019-03-14
TWI852712B (zh) 2024-08-11
IL237328B (en) 2020-06-30
AU2013312868A1 (en) 2015-03-12
IL237328A0 (en) 2015-04-30
TWI699212B (zh) 2020-07-21
KR20220049047A (ko) 2022-04-20
EP4374919A3 (en) 2024-08-21
NZ731864A (en) 2022-07-01
DK2892927T3 (en) 2018-07-16
JP2025024077A (ja) 2025-02-19
JP2018154648A (ja) 2018-10-04
EP3889181B1 (en) 2024-04-24
JP6353838B2 (ja) 2018-07-04
AU2018204346A1 (en) 2018-07-05
KR20210095731A (ko) 2021-08-02
AU2021236538B2 (en) 2023-11-09
KR20150048887A (ko) 2015-05-07
KR102385501B1 (ko) 2022-04-14
CA2883936A1 (en) 2014-03-13
CN104995212A (zh) 2015-10-21
HUE066738T2 (hu) 2024-09-28
ES2981062T3 (es) 2024-10-07
EP2892927B1 (en) 2018-05-09
RU2015108073A (ru) 2016-10-27
RS57520B1 (sr) 2018-10-31
CY1121906T1 (el) 2020-07-31
EP4374919A2 (en) 2024-05-29
SG11201501011WA (en) 2015-03-30
CN118286430A (zh) 2024-07-05
TW201414493A (zh) 2014-04-16
HRP20181227T1 (hr) 2018-10-05
BR112015005048A2 (pt) 2017-11-21
US20170333557A1 (en) 2017-11-23
JP2015534548A (ja) 2015-12-03
RU2018131237A (ru) 2018-10-04
JP2023082091A (ja) 2023-06-13
TW202412839A (zh) 2024-04-01
PT4374919T (pt) 2025-11-19
MX2015002873A (es) 2015-11-13
WO2014039461A1 (en) 2014-03-13
SI2892927T1 (sl) 2018-10-30
EP2892927A1 (en) 2015-07-15
US20230058395A1 (en) 2023-02-23
EP3354663A1 (en) 2018-08-01
AU2018204346B2 (en) 2019-10-03
HK1209132A1 (en) 2016-03-24
TWI814575B (zh) 2023-09-01
EP4374919B1 (en) 2025-10-29
EP4649999A2 (en) 2025-11-19
RU2698907C2 (ru) 2019-09-02
HUE039387T2 (hu) 2018-12-28
AU2021236538A1 (en) 2021-10-21
TWI690328B (zh) 2020-04-11
RU2666630C2 (ru) 2018-09-11
TW201822816A (zh) 2018-07-01

Similar Documents

Publication Publication Date Title
AR092475A1 (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
BR112015011933A8 (pt) Composições bacterianas sinérgicas e métodos de produção e uso das mesmas
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
GT201300319A (es) Coagonistas del receptor de glucagón / glp-1
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
AR089993A1 (es) Macrociclos peptidomimeticos
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
DOP2014000170A (es) Compuestos de imidazopirrolidinona
MX2014014166A (es) Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica.
CL2015002609A1 (es) 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
GEP20186891B (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CL2015002616A1 (es) 7-azabiciclos sustituidos y su uso como modulares del receptor de orexina.
MX2015007169A (es) Uso de inhibidores de la telomerasa para el tratamiento de transtornos mieloproliferativos y neoplasias mieloproliferativas.
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio

Legal Events

Date Code Title Description
FB Suspension of granting procedure